5 Key Takeaways

• 1

  Mark L. Baum emphasizes the moral responsibility of pharmaceutical companies to ensure patient access to beneficial medications.

• 2

  The Vevye Access for All program allows Klarity-C users to switch to Vevye at the same cost, enhancing patient access.

• 3

  Baum actively engages with patients and healthcare providers to understand and address barriers to accessing Vevye.

• 4

  The program reduces out-of-pocket costs for patients and eliminates prescribing restrictions, especially for Medicare Part D.

• 5

  Harrow's efficient portal through PhilRx simplifies prescription changes to Vevye, streamlining the process for healthcare providers.